The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NAMPT inhibition is a novel synthetic lethal therapeutic approach exploiting nuclear-mitochondrial crosstalk in ERCC1-deficient populations.
 
Mehdi Touat
No Relationships to Disclose
 
Tony Sourisseau
No Relationships to Disclose
 
Luc Friboulet
No Relationships to Disclose
 
Nicolas Dorvault
No Relationships to Disclose
 
Roman Chabanon
No Relationships to Disclose
 
Daphné Morel
No Relationships to Disclose
 
Julien Adam
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; HalioDx; Merck Sharp & Dohme; Pfizer; Roche
Research Funding - Pierre Fabre (Inst); Sanofi (Inst)
 
Sylvie Sauvaigo
No Relationships to Disclose
 
David Enot
No Relationships to Disclose
 
Ludovic Bigot
No Relationships to Disclose
 
Clément Pontoizeau
No Relationships to Disclose
 
Frédéric Bouillaud
No Relationships to Disclose
 
Ken Olaussen
No Relationships to Disclose
 
Gérard Pierron
No Relationships to Disclose
 
Alain Sarasin
No Relationships to Disclose
 
Anne Lombès
No Relationships to Disclose
 
Alan Ashworth
No Relationships to Disclose
 
Christopher J. Lord
No Relationships to Disclose
 
Jean-Charles Soria
No Relationships to Disclose
 
Sophie Postel-Vinay
No Relationships to Disclose